157 related articles for article (PubMed ID: 15670952)
21. QSAR study of substituted 1,3,4-oxadiazole naphthyridines as HIV-1 integrase inhibitors.
Ravichandran V; Shalini S; Sundram K; Sokkalingam AD
Eur J Med Chem; 2010 Jul; 45(7):2791-7. PubMed ID: 20347187
[TBL] [Abstract][Full Text] [Related]
22. Cluster analysis and two-dimensional quantitative structure-activity relationship (2D-QSAR) of Pseudomonas aeruginosa deacetylase LpxC inhibitors.
Kadam RU; Roy N
Bioorg Med Chem Lett; 2006 Oct; 16(19):5136-43. PubMed ID: 16879960
[TBL] [Abstract][Full Text] [Related]
23. Analysis of binding parameters of HIV-1 integrase inhibitors: correlates of drug inhibition and resistance.
Loizidou EZ; Zeinalipour-Yazdi CD; Christofides T; Kostrikis LG
Bioorg Med Chem; 2009 Jul; 17(13):4806-18. PubMed ID: 19450984
[TBL] [Abstract][Full Text] [Related]
24. Discovery and structure-activity relationship studies of a unique class of HIV-1 integrase inhibitors.
Dayam R; Sanchez T; Neamati N
ChemMedChem; 2006 Feb; 1(2):238-44. PubMed ID: 16892356
[TBL] [Abstract][Full Text] [Related]
25. Pharmacophore modelling and atom-based 3D-QSAR studies on N-methyl pyrimidones as HIV-1 integrase inhibitors.
Reddy KK; Singh SK; Dessalew N; Tripathi SK; Selvaraj C
J Enzyme Inhib Med Chem; 2012 Jun; 27(3):339-47. PubMed ID: 21699459
[TBL] [Abstract][Full Text] [Related]
26. Docking-based CoMFA and CoMSIA study of azaindole carboxylic acid derivatives as promising HIV-1 integrase inhibitors.
Yu S; Wang P; Li Y; Liu Y; Zhao G
SAR QSAR Environ Res; 2013 Oct; 24(10):819-39. PubMed ID: 23988186
[TBL] [Abstract][Full Text] [Related]
27. A platform for designing HIV integrase inhibitors. Part 2: a two-metal binding model as a potential mechanism of HIV integrase inhibitors.
Kawasuji T; Fuji M; Yoshinaga T; Sato A; Fujiwara T; Kiyama R
Bioorg Med Chem; 2006 Dec; 14(24):8420-9. PubMed ID: 17005407
[TBL] [Abstract][Full Text] [Related]
28. A simple clustering technique to improve QSAR model selection and predictivity: application to a receptor independent 4D-QSAR analysis of cyclic urea derived inhibitors of HIV-1 protease.
Senese CL; Hopfinger AJ
J Chem Inf Comput Sci; 2003; 43(6):2180-93. PubMed ID: 14632470
[TBL] [Abstract][Full Text] [Related]
29. HIV-1 integrase pharmacophore: discovery of inhibitors through three-dimensional database searching.
Nicklaus MC; Neamati N; Hong H; Mazumder A; Sunder S; Chen J; Milne GW; Pommier Y
J Med Chem; 1997 Mar; 40(6):920-9. PubMed ID: 9083480
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of human immunodeficiency virus type I integrase by naphthamidines and 2-aminobenzimidazoles.
Middleton T; Lim HB; Montgomery D; Rockway T; Tang H; Cheng X; Lu L; Mo H; Kohlbrenner WE; Molla A; Kati WM
Antiviral Res; 2004 Oct; 64(1):35-45. PubMed ID: 15451177
[TBL] [Abstract][Full Text] [Related]
31. 3D-QSAR models on clinically relevant K103N mutant HIV-1 reverse transcriptase obtained from two strategic considerations.
San Juan AA
Bioorg Med Chem Lett; 2008 Feb; 18(3):1181-94. PubMed ID: 18155520
[TBL] [Abstract][Full Text] [Related]
32. Linear indices of the "molecular pseudograph's atom adjacency matrix": definition, significance-interpretation, and application to QSAR analysis of flavone derivatives as HIV-1 integrase inhibitors.
Marrero-Ponce Y
J Chem Inf Comput Sci; 2004; 44(6):2010-26. PubMed ID: 15554670
[TBL] [Abstract][Full Text] [Related]
33. Pharmacophore development and docking studies of the hiv-1 integrase inhibitors derived from N-methylpyrimidones, Dihydroxypyrimidines, and bicyclic pyrimidinones.
Telvekar VN; Patel KN
Chem Biol Drug Des; 2011 Jul; 78(1):150-60. PubMed ID: 21518263
[TBL] [Abstract][Full Text] [Related]
34. Design and synthesis of substituted 4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-carboxamides, novel HIV-1 integrase inhibitors.
Langford HM; Williams PD; Homnick CF; Vacca JP; Felock PJ; Stillmock KA; Witmer MV; Hazuda DJ; Gabryelski LJ; Schleif WA
Bioorg Med Chem Lett; 2008 Jan; 18(2):721-5. PubMed ID: 18078751
[TBL] [Abstract][Full Text] [Related]
35. Triketoacid inhibitors of HIV-integrase: a new chemotype useful for probing the integrase pharmacophore.
Walker MA; Johnson T; Ma Z; Banville J; Remillard R; Kim O; Zhang Y; Staab A; Wong H; Torri A; Samanta H; Lin Z; Deminie C; Terry B; Krystal M; Meanwell N
Bioorg Med Chem Lett; 2006 Jun; 16(11):2920-4. PubMed ID: 16546383
[TBL] [Abstract][Full Text] [Related]
36. Pharmacophore-based design of HIV-1 integrase strand-transfer inhibitors.
Barreca ML; Ferro S; Rao A; De Luca L; Zappalà M; Monforte AM; Debyser Z; Witvrouw M; Chimirri A
J Med Chem; 2005 Nov; 48(22):7084-8. PubMed ID: 16250669
[TBL] [Abstract][Full Text] [Related]
37. Naphthoxazepine inhibitors of HIV-1 integrase: synthesis and biological evaluation.
Garofalo A; Grande F; Brizzi A; Aiello F; Dayam R; Neamati N
ChemMedChem; 2008 Jun; 3(6):986-90. PubMed ID: 18383063
[TBL] [Abstract][Full Text] [Related]
38. Computational design of novel fullerene analogues as potential HIV-1 PR inhibitors: Analysis of the binding interactions between fullerene inhibitors and HIV-1 PR residues using 3D QSAR, molecular docking and molecular dynamics simulations.
Durdagi S; Mavromoustakos T; Chronakis N; Papadopoulos MG
Bioorg Med Chem; 2008 Dec; 16(23):9957-74. PubMed ID: 18996019
[TBL] [Abstract][Full Text] [Related]
39. Active site binding modes of curcumin in HIV-1 protease and integrase.
Vajragupta O; Boonchoong P; Morris GM; Olson AJ
Bioorg Med Chem Lett; 2005 Jul; 15(14):3364-8. PubMed ID: 15950462
[TBL] [Abstract][Full Text] [Related]
40. Rational design based on bioactive conformation analysis of pyrimidinylbenzoates as acetohydroxyacid synthase inhibitors by integrating molecular docking, CoMFA, CoMSIA, and DFT calculations.
He YZ; Li YX; Zhu XL; Xi Z; Niu C; Wan J; Zhang L; Yang GF
J Chem Inf Model; 2007; 47(6):2335-44. PubMed ID: 17887745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
